- Brinzolamide
- Dorzolamide HCl
| TopiramateGluR5 receptor antagonist,anticonvulsant |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 100.00%
- COA (Certificate Of Analysis)
- HPLC
- MS (Retest)
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
| Cell experiment [1]: | |
Cell lines | Neurons |
Preparation method | The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20 °C for several months. |
Reaction Conditions | 25 ~ 400 μM |
Applications | In dissociated neurons, Topiramate inhibited the persistent fraction of Na+ current in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male NIH Swiss mice |
Dosage form | 25 ~ 100 mg/kg; i.p. |
Applications | Topiramate (25 ~ 100 mg/kg, i.p.) produced a dose-dependent elevation in the threshold for clonic seizures induced by intravenous infusion of ATPA, a selective agonist of GluR5 kainate receptors. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Taverna S, Sancini G, Mantegazza M, Franceschetti S, Avanzini G. Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther. 1999 Mar;288(3):960-8. [2]. Kaminski RM, Banerjee M, Rogawski MA. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology. 2004 Jun;46(8):1097-104. | |
Topiramate Dilution Calculator
calculate
Topiramate Molarity Calculator
calculate
| Cas No. | 97240-79-4 | SDF | Download SDF |
| Synonyms | N/A | ||
| Chemical Name | [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyl-5,5a,8a,8b-tetrahydrodi[1,3]dioxolo[4,5-a:5",3"-d]pyran-3a-yl]methyl sulfamate | ||
| Canonical SMILES | CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C | ||
| Formula | C12H21NO8S | M.Wt | 339.36 |
| Solubility | ≥16.95 mg/mL in DMSO, ≥24.1 mg/mL in EtOH, ≥2.22 mg/mL in H2O with ultrasonic | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
Topiramate, a novel anticonvulsant drug, is a widely used antiepileptic agent. The drug has been reported to interact with various ion channel types, such as AMPA/kainate receptors, voltage-sensitive Na+ channels, NMDA receptors and GABA receptors [1,2].
In vitro:In principal neurons of the rat basolateral amygdala, low concentrations of topiramate selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by kainate receptors with the GluR5 subunit with an IC50 value of 0.5 μM. Topiramate also partially depressed predominantly AMPA-receptor-mediated EPSCs with lower efficacy [1]. In dissociated neocortical slices, low concentrations of TPM (25–30 μM) slightly inhibited the persistent fraction of Na+ current and reduced the Na+-dependent long-lasting action potential shoulders evoked in layer V pyramidal neurons after Ca2+ and K+ current blockade. TPM (100 μM) had no effects on the voltage dependence of activation but induced a leftward shift of the steady-state INaf inactivation curve [3].
In vivo: TPM treatment significantly improved the 24-h neurological deficit scores (high dose, 1.17 ± 0.41; low dose, 1.75 ± 0.5; p < 0.05 for both doses). The percentage of infarct volume (low dose, 22.9 ± 8.9%, p = 0.002; high dose 7.6 ± 3.4%, p < 0.001) reduced when compared with the controls (infarct size, 54.2 ± 9.0%; neurobehavior score, 2. 67 ± 0.52). Higher dose of TPM induced more neuroprotection than that of lower dose (p < 0.05). In a rat model of focal ischemia, treatment with TPM 2 h after MCA embolization resulted in neuroprotective effect in a dose- and use-dependent manner [2]. Topiramate (25-100 mg/kg, i.p.) dose-dependently elevated the threshold for clonic seizures induced by infusion of a selective agonist of GluR5 kainate receptors ATPA [4]. Topiramate (i.p) effectively suppressed acute seizures induced by perinatal hypoxia in a dose-dependent manner with an ED50 of 2.1 mg/kg [5]. Topiramate (20 and 40 mg/kg i.p.) dose-dependently inhibited both tonic and absence-like seizures. In DBA/2 mice, topiramate inhibited sound-induced seizures with ED50 of 8.6 mg/kg (p.o) [6].
References:[1] Gryder D S, Rogawski M A. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons[J]. The Journal of neuroscience, 2003, 23(18): 7069-7074.[2] Yang Y, Shuaib A, Li Q, et al. Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization[J]. Brain research, 1998, 804(2): 169-176.[3] Taverna S, Sancini G, Mantegazza M, et al. Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate[J]. Journal of Pharmacology and Experimental Therapeutics, 1999, 288(3): 960-968.[4] Kaminski R M, Banerjee M, Rogawski M A. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist[J]. Neuropharmacology, 2004, 46(8): 1097-1104.[5] Koh S, Jensen F E. Topiramate blocks perinatal hypoxia‐induced seizures in rat pups[J]. Annals of neurology, 2001, 50(3): 366-372.[6] Nakamura J, Tamura S, Kanda T, et al. Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice[J]. European journal of pharmacology, 1994, 254(1-2): 83-89.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
